Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Liily's older GLP-1 drug, Trulicity, meanwhile ... However, Lilly saw strength in other drugs as well, with overall non-incretin revenue growing 20%. Verzenio, which is used to treat HR+, HER2 ...

On December 4, 2023, Roche Holding AG (OTCMKTS: RHHBY) announced a $2.7 billion buyout of privately held Carmot Therapeutics ...

Studies suggest that weight loss induced by glucagon-like peptide-1 (GLP-1) drugs can also cause ... “Since the rise of incretin therapies like Wegovy and Mounjaro, scientists have been ...

On December 4, 2023, Roche Holding AG RHHBY announced a $2.7 billion buyout of privately held Carmot Therapeutics for its incretin-based GLP-1 therapies including dual GLP-1/GIP treatment CT-388 ...